CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity
The acquisition of the U.S.-headquartered CDMO expands CordenPharma's manufacturing footprint in South Carolina and China, offering global customers broader production options
CordenPharma has entered into an agreement to acquire AmbioPharm, a peptide contract development and manufacturing organization headquartered in the United States. AmbioPharm currently operates manufacturing facilities in North Augusta, South Carolina, and Shanghai, China. This acquisition is designed to strengthen CordenPharma's peptide manufacturing capabilities in the United States and broaden its global expertise in complex peptide active pharmaceutical ingredients.[1][2]
Through this acquisition, CordenPharma will broaden its peptide active pharmaceutical ingredient development and manufacturing capabilities, with a focus on complex peptide programs. The transaction is set to expand CordenPharma's upstream and downstream peptide manufacturing footprint. By doing so, it adds further capacity for U.S.-based peptide active pharmaceutical ingredient supply to the company's existing operations.[1][2]
Furthermore, the acquisition brings AmbioPharm's Shanghai-based production options into CordenPharma's network, making these facilities available to global customers. The deal bolsters CordenPharma's overall capabilities as a peptide contract development and manufacturing organization. Ultimately, this integration provides customers with broader choices in manufacturing lines and improved scale-up pathways.[1][2]
